Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 6/2012

Open Access 01-12-2012 | REVIEW

Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?

Authors: Andrea Gombos, Otto Metzger-Filho, Lissandra Dal Lago, Ahmad Awada-Hussein

Published in: Investigational New Drugs | Issue 6/2012

Login to get access

Summary

Insulin like growth factor receptor (IGF-1R) targeting became one of the most investigated areas in anticancer drug development during the last decade. Strategies aiming to block IGF-1R activity include monoclonal antibodies, tyrosine kinase inhibitors and anti-ligands antibodies. Initial enthusiasm quickly encountered challenges. Unfortunately the validation of the efficacy of IGF-1R targeted agents in large clinical trials failed, however anecdotal single agent activity was seen in early studies. Consequently, questions regarding the selection of right target population and the appropriate trial design are arising. Despite the plethora of clinical trials conducted no predictive biomarker has been validated so far and resistance mechanisms to IGF-1R inhibitors remain unclear. The other issue to be addressed is how to best combine IGF-1R inhibitors with other therapeutic approaches. This review highlights the most relevant clinical data emphasizing the main tumor types where IGF-1R inhibition showed potential interest. We also tried to extract based on clinical and translational data some candidate biomarkers that could help better to select patient population who potentially could benefit most from this therapeutic approach.
Literature
1.
Ouban A, Muraca P, Yeatman T et al (2003) Expression and Distribution of Insulin-Like Growth Factor-1 Receptor in Human Carcinomas. Hum Pathol 34:803–808PubMedCrossRef
2.
Gualberto A, Pollak M (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinicl trial results and future directions. Oncogene 28:1–13CrossRef
3.
Valentinis B, Baserga R (2001) IGF-I receptor signalling in transformation and differentiation. J Clin Pathol: Mol Pathol 54:133–137CrossRef
4.
Baserga R, Peruzzi F, Reiss K (2003) The IGF-1 Receptor in Cancer Biology. Int J Cancer 107:873–877PubMedCrossRef
5.
Samani AA, Yakar S, LeRoith D et al (2007) The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights. Endocr Rev 28:20–47PubMedCrossRef
6.
Chitnis MM, Yuen SP, Protheroe SA et al (2008) The Type 1 Insulin-Like Growth Factor Receptor Pathway. Clin Cancer Res 14:6364–6370PubMedCrossRef
7.
Pollak M (2008) Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 8:915–928PubMedCrossRef
8.
Dunn SE, Hardman RA, Kari FW et al (1997) Insulin-like Growth Factor 1 (IGF-1) Alters Sensitivity of HBL100 Human Breast Cancer Cells by Inhibition of Apoptosis Induced by Divers Anticancer drugs. Cancer Res 57:2687–2693PubMed
9.
Eckstein N, Servan K, Hildebrand B, Politz A et al (2009) Hyperactivation of the Insulin-like Growth Factor Receptor I Signalling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells. Cancer Res 69:2296–3003CrossRef
10.
Natha R, Yuan LX, Zhang B et al (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerisation contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118–11128CrossRef
11.
Lu Y, Zi X, Zhao Y et al (2001) Insulin-like growth factor-I receptor signalling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852–1857PubMedCrossRef
12.
Knowlden JM, Jones HE, Barrow D et al (2008) Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin—like growth factor receptor signaling: implication for Gefitinib (‘Iressa’) response and resistance. Breast Cancer Res Treat 111:79–91PubMedCrossRef
13.
Jones HE, Goddard L, Gee GM et al (2004) Insulin-like growth factor I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11:793–814PubMedCrossRef
14.
Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like Growth Factor Receptor I Mediates Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Primary Human Glioblastoma Cells through Continued Activation of Phosphoinositide 3 -Kinase Signaling. Cancer Res 62:200–207PubMed
15.
Buck E, Eyzaguirre A, Rosenfeld-Franklin M et al (2008) Feedback Mechanisms Promote Coopeativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors. Cancer Res 68:8322–8332PubMedCrossRef
16.
Huang F, Greer A, Hurlburt W et al (2009) The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors. Cancer Res 69:161–170PubMedCrossRef
17.
Hu PY, Patil BS, Panasiewitz M et al (2008) Heterogeneity of receptor Function in Colon Carcinoma Cells Determined by Cross-talk between Type I Insulin-like Growth Factor Receptor and Epidermal Growth Factor Receptor. Cancer Res 68:8004–8013PubMedCrossRef
18.
Chakraborty AK, Ke L, DiGiovanna MP (2008) Co-Targeting Insulin-Like Growth Factor I Receptor and Her2: Dramatic Effects of HER2 Inhibitors on Nonoverexpressing Breast Cancer. Cancer Res 68:1538–1545PubMedCrossRef
19.
Jin Q, Esteva FJ (2008) Cross Talk Between the ErbB/HER Family and Type I Insulin-Like Growth Factor Receptor Signalling Pathway in Breast Cancer. J Mammary Gland Biol Neoplasia 13:485–498PubMedCrossRef
20.
Haluska P, Carboni JM, TenEyck C et al (2008) HER receptor signalling confers resistance to the insuline-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 7:2589–2608PubMedCrossRef
21.
Browne BC, Crown J, Venkatesan N et al (2011) Inhibition of IGF1R activity enhances response to trastuzumab in HER-2 positive breast cancer cells. Ann Oncol 22:68–73PubMedCrossRef
22.
Wan X, Harkavy B, Shen N et al (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26:1932–1940PubMedCrossRef
23.
Haruta T, Uno T, Kawahara J et al (2009) A Rapamycin-Sensitive Pathway Down-Regulates Insulin Signalling via Phosphorylation and Proteasomal Degradation of Insulin Receptor Substrate-1. Molecular Endocrinol 14:783–794CrossRef
24.
Takano A, Usui I, Haruta T et al (2001) Mammalian Target of Rapamycin Pathway Regulates Insulin Signalling via Subcelular Redistribution of Insulin Receptor Substrate 1 and Integrates Nutritional Signals and Metabolic Signals of Insulin. Mol an Cel Biol 21:5050–5062CrossRef
25.
Adélaide J, Finetti P, Bekhouche I et al (2007) Integrated Profiling of Basal and Luminal Breast Cancers. Cancer Res 67:11565–11575PubMedCrossRef
26.
Dziadziuszko R, Merrick DT, Samir E (2010) Insulin-like Growth Factor Receptor I (IGF1R) Gene Copy Number Is Associated With Survival in Operable Non-Small-Cell Lung Cancer: A Comparison Between IGF1R Fluorescent In Situ Hybridization, Protein Expression, and mRNA Expression. J Clin Oncol 28:2174–2180PubMedCrossRef
27.
Gong Y, Yao E, Shen R et al (2009) High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507). PLoS One 4:e7273PubMedCrossRef
28.
Armengol G, Knuutila S, Lluis F et al (2000) DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic Aden carcinoma. Cancer Genet Cytogenet 116:133–141PubMedCrossRef
29.
Zha J, O’Brien C, Savage H et al (2009) Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 8:2110–2121PubMedCrossRef
30.
Pitts TM, Tan AC, Kulikowski GN et al (2010) Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development. Clin Cancer Res 16:3193–3204PubMedCrossRef
31.
Tarn C, Rink L, Flieder D et al (2008) Insulin-like growth factor receptor is a potential therapeutic target for gastrointestinal stromal tumors. PNAS 24:8387–8392CrossRef
32.
Merrick DT, Dziadziuszko R, Szostakiewicz B, Szymanowska A, Rzyman W, Jassem E et al (2007) High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 25 (18_suppl):Abst 7550.
33.
Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A et al (2009) High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20:842–849PubMedCrossRef
34.
Cappuzzo F, Tallini G, Finocchiaro G et al (2006) Insulin-like growth factor receptor & (IGFR-1) is significantly associated with longer survival in non-small cell lung cancer (NSCLC) patients. Ann Oncol 17:1120–1127PubMedCrossRef
35.
Gualberto A, Dolled-Filhart M, Gustavson M et al (2010) Molecular Analysis of Non-Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition. Clin Cancer Res 16:4654–4665PubMedCrossRef
36.
Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F et al (2009) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27:2516–2522PubMedCrossRef
37.
Jassem J, Langer CJ, Karp DD et al (2010) Randomized, open label, phase III trial of figitumomab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer. J Clin Oncol 28 (15 suppl): Abstr 7500
38.
39.
Rikhof B, de Jong S, Suurmeijer AJH et al (2009) The insulin-like growth factor system and sarcomas. J Pathol 217:469–482PubMedCrossRef
40.
Olmos D, Tan DS, Jones RL et al (2010) Biological Rationale and Current Clinical Experience With Anti-Insulin-Like Growth Factor 1 Receptor Monoclonal Antibodies in Treating Sarcoma. The Cancer Journal 16:183–194PubMedCrossRef
41.
Braconi C, Bracci R, Bearzi I et al (2008) Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 19:1293–1298PubMedCrossRef
42.
Pappo AS, Patel S, Crowley J et al (2010) Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients with recurrent or refractory Ewing’s sarcoma family of tumors (ESFT): Results of a phase II SARCC study. J Clin Oncol 28: 15s, 2010 (suppl; abstr 10000)
43.
Tap WD, Demetri GD, Barnette P et al. AMG 479 in relapsed or refractory Ewing’s family tumors (EFT) or desmoplastic small round cell tumors (DSCRCT): Phase II results. J Clin Oncol 28 (15 suppl): Abstr 10001
44.
Olmos D, Postel-Vinay S, Molife LR et al (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase I expansion cohort study. Lancet Oncol 11:129–135PubMedCrossRef
45.
46.
47.
48.
Shimizu S, Hasegawa T, Tani Y et al (2005) Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysis. Human Pathol 36:448–449CrossRef
49.
Key TJ, Appleby PN, Reeves GK et al (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11:530–542PubMedCrossRef
50.
Creighton CJ, Casa A, Lazard Z et al (2008) Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 26:4078–4085PubMedCrossRef
51.
Tolcher AW, Ptnaik A, Till E et al (2008) A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor 1 receptor) antagonist, in patients (pts) with advanced solid tumors (ST). J Clin Oncol 26 (May 20 suppl): Abstr 3582
52.
Tolcher AW, Rothenberg ML, Rodon J et al (2007) A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 25 (June 20 Suppl): Abstr 3002
53.
54.
55.
56.
57.
58.
Di Cosimo S, Bendell JC, Cervantes-Ruiperez A et al (2010) A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol 28 (15 suppl): Abstr 3008
59.
Naing A, LoRusso P, Gupta S et al (2010) Dual inhibition of IGFR and mTOR pathways. J Clin Oncol 28 (15 suppl): Abstr 3007
60.
West AN, Neale GA, Pounds S et al (2007) Gene Expression Profiling of Childhood Adrenocortical Tumors. Cancer Res 67:600–608PubMedCrossRef
61.
Barlaskar FM, Spalding AC, Heaton JH et al (2009) Preclinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical Carcinoma. J Clin Endocrinol Metab 94:204–212PubMedCrossRef
62.
Carden CP, Frentzas S, Langham M et al (2009) Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors. J Clin Oncol 27 (15 suppl): Abstr 3544
63.
Haluska P, Worden F, Olmos D et al (2010) Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 65:765–773PubMedCrossRef
64.
Baselga J, Gelmon KA, Verma S et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138–1144PubMedCrossRef
65.
66.
Dong J, Demarest SJ, Sereno A et al (2010) Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response. Mol Cancer Ther 9:2693–604CrossRef
67.
Olmos D, Basu B, de Bono J (2010) Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies. Mol Cancer Ther 9:2447–2449PubMedCrossRef
Metadata
Title
Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?
Authors
Andrea Gombos
Otto Metzger-Filho
Lissandra Dal Lago
Ahmad Awada-Hussein
Publication date
01-12-2012
Publisher
Springer US
Published in
Investigational New Drugs / Issue 6/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-012-9811-0

Other articles of this Issue 6/2012

Investigational New Drugs 6/2012 Go to the issue

REVIEW

Aurora kinase inhibitors: Progress towards the clinic

PRECLINICAL STUDIES

Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression

PRECLINICAL STUDIES

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

PRECLINICAL STUDIES

The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines

PRECLINICAL STUDIES

Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients

PRECLINICAL STUDIES

(+)-Episesamin exerts anti-neoplastic effects in human hepatocellular carcinoma cell lines via suppression of nuclear factor-kappa B and inhibition of MMP-9
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits